RxDoctor Payments Data

Amnerys Garcia, MD

Neurology · Hialeah, FLNPI 1780001909

Payments from drug & device makers

$204,067in general payments, 2019–2025

Across 337 payments — averaging $605.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$174K
  • Novartis$23K
  • AbbVie$1K
  • UCB, Inc.$940
  • Catalyst Pharmaceuticals, Inc.$805
  • Eisai Inc.$777
  • plus $3K from 21 others

What the payments were for

  • Food & beverage$6,81098%
  • Education$1222%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$204,067 in reported general payments places this provider in the 85th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$393,932
Medicare patients
519
Services billed
3,240

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate97$507,918
UbrelvyUbrogepant66$96,398
RytaryCarbidopa/Levodopa115$89,788
QuliptaAtogepant67$75,659
NeuproRotigotine65$55,139
Nurtec OdtRimegepant Sulfate26$47,978
GocovriAmantadine Hcl13$41,972
Memantine Hcl ErMemantine Hcl201$24,891
Rasagiline Mesylate257$18,448
NamzaricMemantine Hcl/Donepezil Hcl21$16,026
Emgality PenGalcanezumab-Gnlm19$15,214
RivastigmineRivastigmine Tartrate404$11,563
XareltoRivaroxaban17$8,795
Carbidopa-LevodopaCarbidopa/Levodopa1,007$8,462
Gabapentin1,506$7,623

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$307$507,91897 claims
AbbVieUbrelvy, Qulipta, Namzaric$1,102$188,083154 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$52$91,885166 claims
UCB, Inc.Neupro$940$55,13965 claims
PfizerNurtec Odt, Dilantin$636$51,24547 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,434 neurology providers in Florida.

Other neurology in Hialeah

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →